Trial ID or NCT#

NCT02415881

Status

RECRUITING

Purpose

Phase I trial to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent.

Official Title

Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Michael J. Kaplan
Head and neck surgical oncologist, Surgical oncologist, Head and neck surgeon, Otolaryngologist
Professor of Otolaryngology - Head and Neck Surgery and, by courtesy, of Neurosurgery at the Stanford University Medical Center
Vasu Divi
Otolaryngologist, Head and neck surgical oncologist, Surgical oncologist, Head and neck surgeon
Assistant Professor of Otolaryngology - Head and Neck Surgery at the Stanford University Medical Center
Davud Sirjani
Otolaryngologist, Head and neck surgeon, Head and neck surgical oncologist
Clinical Assistant Professor, Otolaryngology (Head and Neck Surgery)
Eben Rosenthal
Otolaryngologist
Professor of Otolaryngology-Head and Neck Surgery and of Radiology (Molecular Imaging Program at Stanford)

Contact us to find out if this trial is right for you.

CONTACT

Nicholas Oberhelman
(650) 724-3866